BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BPI-572270 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BPI-572270\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07435038-2419@assetmemo.bio
DTSTAMP:20261121T005423Z
DTSTART;VALUE=DATE:20281228
DTEND;VALUE=DATE:20281229
SUMMARY:BPI-572270: Phase 1/2 readout est. (NCT07435038)
DESCRIPTION:BPI-572270\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: St
 udy of BPI-572270 in Patients With Advanced Solid Tumors Harboring Specifi
 c Mutations in RAS\nEstimated primary completion: 28 December 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/bpi-572270#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07435038
URL:https://assetmemo.bio/drug/bpi-572270#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
